AUTHORS
Moataz Ellithi, MD, Krishna Gundabolu, MBBS2, Michael Haddadin, MBBS, MS3, Snegha Ananth, MD4, Lori Maness, MD5, Tanya Wildes, MD,MSc6, Christopher Wichman7, Vijaya Raj Bhatt, MBBS, MS8
AFFILIATIONS
1 University of Nebraska Medical Center, Omaha, Nebraska, United States
2 University of Nebraska Medical Center, Omaha, Nebraska, United States
3 University of Nebraska Medical Center, Omaha, Nebraska, United States
4 University of Nebraska Medical Center, Omaha, Nebraska, United States
5 University of Nebraska Medical Center, Omaha, Nebraska, United States
6 University of Nebraska Medical Center, Omaha, Nebraska, United States
7 University of Nebraska Medical Center, Omaha, Nebraska, United States
8 University of Nebraska Medical Center, Omaha, Nebraska, United States
ABSTRACT
Background and Significance: Allogeneic hematopoietic cell transplantation (Allo-HCT) is increasingly utilized in older adults but older recipients face disproportionate risks due to limited physiologic reserve leading to slower recovery, and a greater burden of treatment-related toxicity. Post-transplant cyclophosphamide (PTCy) has transformed graft-vs-host disease (GVHD) prophylaxis across donor types, but the standard dose of 50 mg/kg on days +3 and +4 has not been optimized for this vulnerable population. In older adults, this dose is associated with risks of prolonged cytopenias, hemorrhagic cystitis, infections, and cardiotoxicity, all of which compromise health-related quality of life (HRQoL), increase non-relapse mortality (NRM), and impair post-transplant recovery. Despite preclinical and clinical evidence supporting the rationale for attenuated dosing of PTCy, no randomized trials have directly compared attenuated versus standard PTCy dosing in older adults, representing a critical evidence gap that limits practice change.
Study Design and Methods: This is a single-center phase II randomized controlled trial comparing attenuated-dose versus standard-dose PTCy for GVHD prophylaxis in older adults undergoing reduced-intensity allo-HCT from HLA-matched donors. Key inclusion criteria include adults (≥60 years) with hematological malignancies who are planned to undergo reduced intensity conditioning allo-HCT using HLA 8/8 matched related or unrelated donor. Key exclusion criteria include primary myelofibrosis, prior allo-HCT, planned high-dose cyclophosphamide in the conditioning regimen (e.g. BuCy), HLA mismatched or haploidentical donor transplants, advanced liver disease, creatinine clearance <40 ml/min/1.73m², or left ventricular ejection fraction <50%. Study participants will be randomized 1:1 to PTCy 25 mg/kg vs. 50 mg/kg on days +3 and +4. Both arms will receive sirolimus and mycophenolate mofetil. Randomization will be stratified based on age (60-69 years vs. ≥70 years). The primary endpoint is HRQoL at three months post-transplant, measured by the Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT). Secondary endpoints include functional outcomes (Katz activities of daily living, gait speed, Lawton instrumental activities of daily living, Clock-in-the-Box Test, Fried Frailty Index, falls, and Geriatric Depression Scale-15), GVHD-free relapse-free survival (GRFS), overall survival (OS), event-free survival (EFS), relapse, NRM, grade II-IV acute GVHD, chronic GVHD, time to neutrophil and platelet engraftment, grade ≥3 adverse events at 1 month by Common Terminology Criteria for Adverse Events (CTCAE) grading, and grade ≥2 infections at 6 months by Blood and Marrow Transplant Clinical Trials Network (BMT CTN) grading. The target accrual is 126 participants (63 per arm), allowing for up to 20% attrition per arm while maintaining >80% power to detect a clinically meaningful difference in FACT-BMT scores between groups. The primary analysis will use a linear mixed model adjusting for baseline FACT-BMT and sex under an intention-to-treat approach. Continuous functional outcomes will be analyzed with linear mixed models and binary outcomes with logistic regression, with adjustment for relevant baseline covariates. Missing data will be addressed using multiple imputation or inverse probability weighting, as appropriate. OS, PFS, and GRFS will be analyzed using Kaplan-Meier and log-rank methods, while relapse and NRM will be evaluated using Fine-Gray competing-risk models. Cox proportional hazards models will adjust for baseline prognostic factors, including disease risk, comorbidity index, and donor characteristics. Acute and chronic GVHD will be summarized by grade and cumulative incidence. The study is currently open and accruing patients (Clinicaltrials.gov # NCT06799195).
DISCLOSURES
Moataz Ellithi, MD: No relevant conflicts of interest to declare.